Talent Squeeze at FDA: Bad News for Drug Reviews, Good News for Merck?
This article was originally published in RPM Report
Executive Summary
FDA's drug review managers and staff are showing signs of wear and tear from the tough political climate for the agency. Some key staff have departed. Merck took advantage of the turmoil to get a manager with knowledge of the endocrine area, where the taranabant NDA will be filed.
You may also be interested in...
Former FDA ODE II Director Meyer Building New Regulatory Sciences Center at UVA
Bob Meyer, a veteran of both sides of the FDA drug regulatory process from top-level positions in FDA’s drug review office and the Merck regulatory strategy and policy group, is trying to create a new regulatory science center at the University of Virginia that could add to FDA’s close-by academic support resources.
Reinforcements At Last: CDER Hiring Process Well Underway
FDA is in the midst of a hiring frenzy to rebuild a severely understaffed agency. The good news is that the center for drugs is about halfway through the process, with the Office of New Drugs receiving the bulk of new hires. It's not equal across review divisions-some are receiving more new people than others.
Reinforcements At Last: CDER Hiring Process Well Underway
FDA is in the midst of a hiring frenzy to rebuild a severely understaffed agency. The good news is that the center for drugs is about halfway through the process, with the Office of New Drugs receiving the bulk of new hires. It's not equal across review divisions-some are receiving more new people than others.